Novartis Venture Fund
Waling Benamer is a Multi-Discipline Engineer at Novartis, with experience in GMP production of CAR T-cell therapies for leukemia and lymphoma since July 2018. Responsibilities include serving as the subject matter expert (SME) for integrating new bioreactor technologies. Prior experience at Rutgers University includes roles as a Technical Services Representative, focusing on lab maintenance and technical troubleshooting, and as a Research Assistant in recombinant protein production and animal science, where significant work was conducted on low-expressing Fibroblast Growth Factor-2 and transgenic mouse studies. Waling holds a Bachelor of Science degree in General Biotechnology from Rutgers University.
This person is not in any teams
This person is not in any offices
Novartis Venture Fund
3 followers
Novartis Venture Fund's primary focus is on the development of novel therapeutics and platforms. In their investments, they look for unmet need and clinical impact, novel proprietary science, and understanding of the mechanism, management, and board experience and capital efficiency in the program.